EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN

Objective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arif Qayyum Khan, Hala Mansoor, Javed Iqbal Raja, Raja Yasser Shahbaz, Samina Fida, Muhammad Siddique
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2020
Materias:	hepatitis c virus (hcv) svr 12 Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/144eb38e17b145c0b5e936fe0bcf2179
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:144eb38e17b145c0b5e936fe0bcf2179
record_format	dspace
spelling	oai:doaj.org-article:144eb38e17b145c0b5e936fe0bcf21792021-12-02T19:12:10ZEFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTANdoi.org/10.51253/pafmj.v70i6.34690030-96482411-8842https://doaj.org/article/144eb38e17b145c0b5e936fe0bcf21792020-12-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/3469https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital, Lahore, from Nov 2014 to Mar 2017. Methodology: A total of 182 consecutive patients with age ≥18 years and positive HCV RNA by polymerase chain reaction were included, while patients with haemoglobin of <10 g/dl, albumin <2 g/dl, platelet count of <100/uL, creatinine clearance of <60 mL/min or liver disease caused by non-hepatitis C related causes were excluded from study. Results: Total 129 (70.8%) were treated with dual and 53 (29.1%) with triple therapy. Amongst patients with genotype 3 (158/182), the overall sustained virological response at 12 weeks (SVR 12) was 94.4% in patients with dual therapy while it was 97.3% with triple therapy. In non-cirrhotic patients it was 95% in treatment naïve and 100% in treatment experienced group. While in cirrhotic patients with genotype 3, SVR 12 with dual therapy was 83.3% (p=0.331) and 88.9% in treatment naïve and treatment experienced patients respectively, while it was 100% in both groups with triple therapy. SVR 12 for genotype 1 (21/182) was 100%, both for dual as well as for triple therapy. Haematological side effects dominated the clinical picture with 11.5% suffering from anaemia. Conclusion: Both dual and triple therapy were effective in patients with hepatitis C with acceptable level of side effects, genotype 3 being the most predominant genotype.Arif Qayyum KhanHala MansoorJaved Iqbal RajaRaja Yasser ShahbazSamina FidaMuhammad SiddiqueArmy Medical College Rawalpindiarticlehepatitis c virus (hcv)svr 12MedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 70, Iss 6, Pp 1885-1891 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatitis c virus (hcv) svr 12 Medicine R Medicine (General) R5-920
spellingShingle	hepatitis c virus (hcv) svr 12 Medicine R Medicine (General) R5-920 Arif Qayyum Khan Hala Mansoor Javed Iqbal Raja Raja Yasser Shahbaz Samina Fida Muhammad Siddique EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
description	Objective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital, Lahore, from Nov 2014 to Mar 2017. Methodology: A total of 182 consecutive patients with age ≥18 years and positive HCV RNA by polymerase chain reaction were included, while patients with haemoglobin of <10 g/dl, albumin <2 g/dl, platelet count of <100/uL, creatinine clearance of <60 mL/min or liver disease caused by non-hepatitis C related causes were excluded from study. Results: Total 129 (70.8%) were treated with dual and 53 (29.1%) with triple therapy. Amongst patients with genotype 3 (158/182), the overall sustained virological response at 12 weeks (SVR 12) was 94.4% in patients with dual therapy while it was 97.3% with triple therapy. In non-cirrhotic patients it was 95% in treatment naïve and 100% in treatment experienced group. While in cirrhotic patients with genotype 3, SVR 12 with dual therapy was 83.3% (p=0.331) and 88.9% in treatment naïve and treatment experienced patients respectively, while it was 100% in both groups with triple therapy. SVR 12 for genotype 1 (21/182) was 100%, both for dual as well as for triple therapy. Haematological side effects dominated the clinical picture with 11.5% suffering from anaemia. Conclusion: Both dual and triple therapy were effective in patients with hepatitis C with acceptable level of side effects, genotype 3 being the most predominant genotype.
format	article
author	Arif Qayyum Khan Hala Mansoor Javed Iqbal Raja Raja Yasser Shahbaz Samina Fida Muhammad Siddique
author_facet	Arif Qayyum Khan Hala Mansoor Javed Iqbal Raja Raja Yasser Shahbaz Samina Fida Muhammad Siddique
author_sort	Arif Qayyum Khan
title	EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
title_short	EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
title_full	EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
title_fullStr	EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
title_full_unstemmed	EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
title_sort	efficacy of first available direct-acting antiviral agent in treatment of chronic hepatitis c; results from a single centre in pakistan
publisher	Army Medical College Rawalpindi
publishDate	2020
url	https://doaj.org/article/144eb38e17b145c0b5e936fe0bcf2179
work_keys_str_mv	AT arifqayyumkhan efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan AT halamansoor efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan AT javediqbalraja efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan AT rajayassershahbaz efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan AT saminafida efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan AT muhammadsiddique efficacyoffirstavailabledirectactingantiviralagentintreatmentofchronichepatitiscresultsfromasinglecentreinpakistan
_version_	1718377037277691904

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN

Ejemplares similares